Rigel Pharmaceuticals (RIGL) Receivables - Net (2013 - 2026)

Rigel Pharmaceuticals' Receivables - Net history runs 13 years deep, the most recent figure standing at $49.9 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 1564.83% year-over-year to $49.9 million; the TTM figure through Mar 2026 stood at $49.9 million (up 1564.83% YoY), while the FY2025 annual figure was $51.8 million, up 24.39% from the prior year.
• Receivables - Net was $49.9 million for Q1 2026 at Rigel Pharmaceuticals, down from $51.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $51.8 million in Q4 2025 to a low of $3.0 million in Q1 2025.
• Historically, Receivables - Net has averaged $28.9 million across 5 years, with a median of $28.9 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Receivables - Net slumped 89.28% in 2022, then surged 1564.83% in 2026.
• A 5-year view of Receivables - Net shows it stood at $20.0 million in 2022, then jumped by 52.75% to $30.6 million in 2023, then soared by 36.22% to $41.6 million in 2024, then grew by 24.39% to $51.8 million in 2025, then dropped by 3.51% to $49.9 million in 2026.
• The last three Receivables - Net figures came in at $49.9 million (Q1 2026), $51.8 million (Q4 2025), and $45.9 million (Q3 2025), per Business Quant data.